Active Ingredient History

  • Now
Semagacestat (LY-450139) was a candidate drug for a causal therapy against Alzheimer's disease. It was originally developed by Eli Lilly and Elan, and clinical trials were conducted by Eli Lilly. Phase III trials included over 3000 patients, but in August 2010, a disappointing interim analysis, in which semagacestat performed worse than the placebo, led to the trials being stopped.   Wikipedia

  • SMILES: CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@@H]1C(=O)N(C)CCc2ccccc12
  • Mol. Mass: 361.44
  • ALogP: 0.38
  • ChEMBL Molecule:
More Chemistry
ly411575 | ly 411575 | ly 411,575 | ly-411575 | ly-411,575 | ly411,575 | ly450139 | ly 450139 | ly-450139 | n2-(2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-n1-(5-methyl-6-oxo-6,7-dihydro-5h-dibenzo(b,d)azepin-7-yl)alaninamide | n2-((2s)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-n1-((7s)-5-methyl-6-oxo-6,7-dihydro-5h-dibenzo(b,d)azepin-7-yl)-l-alaninamide | semagacestat


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue